Data as of Nov 4, 2026.
BIOY vs XLVI: Dividend Yield & Total Return
BIOY and XLVI both write options for income.
askIQ about this page
askIQ about BIOY and XLVI
Net assets on Nov 3, 2026: $1.5m for GraniteShares YieldBOOST Biotech ETF and $38m for State Street Health Care Select Sector SPDR Premium Income ETF.
13.6 pts behind XBI
BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
XBI
+19.0%
BIOY
+5.4%
26.1% as cash
13.6 pts behind XBI
Total return, distributions reinvested
13.6 pts behind XBI
BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
XBI
+19.0%
BIOY
+5.4%
13.6 pts behind XBI
26.1% of it arrived as cash. Total return, distributions reinvested. BIOY since launch: paid 26.1%, price −21.9%, total +5.4%, XBI +19.0%, −13.6 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.12.2 pts behind XLV
XLVI over 1 year: paid 13.0%, price +6.1%, total +20.7%, XLV +32.9%, −12.2 pts. Data to Nov 4, 2026.
XLV
+32.9%
XLVI
+20.7%
13.0% of it arrived as cash
12.2 pts behind XLV
Total return, distributions reinvested
12.2 pts behind XLV
XLVI over 1 year: paid 13.0%, price +6.1%, total +20.7%, XLV +32.9%, −12.2 pts. Data to Nov 4, 2026.
XLV
+32.9%
XLVI
+20.7%
12.2 pts behind XLV
13.0% of it arrived as cash. Both charts share one scale, with zero at the line. XLVI over 1 year: paid 13.0%, price +6.1%, total +20.7%, XLV +32.9%, −12.2 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.Pair scorecard
XLVI costs 0.83 points a year less; XLVI is far larger, $38m against $1.5m.
Points (pts) are percentage points.
| Measure | BIOY | XLVI |
|---|---|---|
| Paid and earned | ||
| Total return, 1 year | not published | +20.7% |
| Price change | fell 21.9% (since May 5, 2026) | rose 6.1% (1 year) |
| Return of capital, issuer estimate | 96% of the Sep 22, 2026 payment | 100% of the Nov 5, 2026 payment |
| Against its benchmark | ||
| Benchmark | Biotech, measured through XBI | Health care sector, measured through XLV |
| Cost and size | ||
| Expense ratio | 1.18% | 0.35% |
| Net assets, as of Nov 3, 2026 | $1.5m | $38m |
| Holdings | ||
| Holdings in common | 0% | |
What they share
By the books each fund has filed, BIOY and XLVI hold 0% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Nov 3, 2026.
half
0% in common
Only in one fund ↓
Side by side
As of Nov 4, 2026. Source: ETFIQ. Cash paid: distributions over the window, as a share of the starting price. Payout rate: the latest payment, annualized, over today’s price.
Window by window
| Total return | Cash paid | Against the benchmark | ||||
|---|---|---|---|---|---|---|
| Window | BIOY | XLVI | BIOY | XLVI | BIOY | XLVI |
| 3 months | +6.9% | +6.8% | 14.5% | 3.5% | +2.9 pts | −9.2 pts |
| 6 months | +4.4% | +18.1% | 25.9% | 6.5% | −11.3 pts | −13.4 pts |
| 1 year | – | +20.7% | – | 13.0% | – | −12.2 pts |
| Since launchNot the same days: BIOY May 2026 · XLVI Jul 2025 | +5.4% | +29.9% | 26.1% | 17.2% | −13.7 pts | −14.4 pts |
– means no data for this window. Open this comparison in the app →
BIOY
Over the period from its first trade on May 5, 2026 to Nov 4, 2026, BIOY paid 26.1% of its starting value in cash distributions while its price fell 21.9%. With every distribution reinvested, the fund returned +5.4%. Biotech (XBI) returned +19.0% over the same days, so a holder was behind by 13.6 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 60.7%, paid weekly. GraniteShares estimates that 96% of the distribution paid Sep 22, 2026 was a return of capital (its 19a-1 notice). That is a tax label, not a measure of erosion.
XLVI
Over the year to Nov 4, 2026, XLVI paid 13.0% of its starting value in cash distributions while its price rose 6.1%. With every distribution reinvested, the fund returned +20.7%. Health care sector (XLV) returned +32.9% over the same days, so a holder was behind by 12.2 pts. At its price on Nov 4, 2026 the latest distribution annualizes to 14.0%, paid monthly. State Street estimates that 100% of the distribution paid Nov 5, 2026 was a return of capital (its 19a-1 notice).
Questions people ask
Links are sources, not endorsements. A comparison is not a recommendation.
How this is computed
Overlap adds up the smaller of the two weights for each security both funds hold.
Every number is an ETFIQ calculation with distributions reinvested.
Cite this pageCitation, APA and Markdown
ETFIQ, BIOY against XLVI, data as of Nov 4, 2026. https://etfiq.com/compare/income/bioy-vs-xlvi
ETFIQ. (Nov 4, 2026). BIOY against XLVI. Retrieved from https://etfiq.com/compare/income/bioy-vs-xlvi
[BIOY against XLVI (ETFIQ, Nov 4, 2026)](https://etfiq.com/compare/income/bioy-vs-xlvi)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.